Novavax Stock Is Rising. Investors Cheer Revenue Beat, Vaccine Shift. - Barron's
1. NVAX stock rose 4.1% after beating quarterly revenue expectations. 2. Fourth-quarter revenue was $88 million, exceeding the $84 million estimate. 3. Company shifts focus from COVID-19 vaccines to new development-stage candidates. 4. Projected revenue for this year is between $300 million and $350 million. 5. Analysts forecast NVAX returning to profitability by Q2 with earnings of 46 cents.